HIV drug swap keeps virus in check, study finds
NCT ID NCT00454337
First seen Apr 07, 2026 · Last updated May 11, 2026 · Updated 7 times
Summary
This study looked at whether people with HIV who were already on a successful treatment regimen including enfuvirtide could safely switch to a different drug, raltegravir, without the virus rebounding. 170 adults with suppressed HIV (below 400 copies/mL) were randomly assigned to either stay on enfuvirtide or switch to raltegravir. The main goal was to see if the switch was just as good at keeping the virus under control for 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service des maladies infectieuses et tropicales Hopital Saint Louis
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.